Aerucin Awarded Fast Track for HAP/VAP

Aridis Pharmaceuticals announced that the Food and Drug Administration (FDA) has granted Fast Track designation to Aerucin for the treatment of hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa.

Aerucin is a broadly reactive fully human immunoglobulin G (IgG), mAb targeting P. aeruginosa bacteria that exhibits broad binding to greater than 90% of clinical isolates of P. aeruginosa.

RELATED: Narrow-Spectrum Antibiotic Use for CAP Up After Guideline Implementation

Aerucin is currently under evaluation in a Phase 1 clinical trial to determine its safety and pharmacokinetics in healthy adults. Results are expected to be complete in the fourth quarter of this year.

For more information visit AridisPharma.com.

Loading links....